<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01003639</url>
  </required_header>
  <id_info>
    <org_study_id>NORDIC01</org_study_id>
    <secondary_id>1U10EY017281-01A1</secondary_id>
    <secondary_id>1U10EY017387-01A1</secondary_id>
    <nct_id>NCT01003639</nct_id>
  </id_info>
  <brief_title>Idiopathic Intracranial Hypertension Treatment Trial</brief_title>
  <acronym>IIHTT</acronym>
  <official_title>A Multicenter, Double-blind, Randomized, Placebo-controlled Study of Weight-Reduction and/or Low Sodium Diet Plus Acetazolamide vs Diet Plus Placebo in Subjects With Idiopathic Intracranial Hypertension With Mild Visual Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Luke's-Roosevelt Hospital Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Luke's-Roosevelt Hospital Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Idiopathic intracranial hypertension (IIH), also called pseudotumor cerebri, is a disorder of
      elevated intracranial pressure of unknown cause [Corbett, et al., 1982; Wall, et al., 1991].
      Its incidence is 22.5 new cases each year per 100,000 overweight women of childbearing age,
      and is rising [Garrett, et al., 2004] in parallel with the obesity epidemic. It affects about
      100,000 Americans. Most patients suffer debilitating headaches. Because of pressure on the
      optic nerve (papilledema), 86% have some degree of permanent visual loss and 10% develop
      severe visual loss [Wall, et al., 1991]. Interventions to prevent loss of sight, all with
      unproven efficacy, include diet, diuretics such as acetazolamide, repeated spinal taps, optic
      nerve sheath fenestration surgery, and cerebrospinal fluid (CSF) shunting procedures. The
      purported goal of these therapies is to lower intracranial pressure; however, it is unclear
      which treatments work and by what mechanism. None of these strategies has been verified by
      properly designed clinical trials. Thus, there is confusion, uncertainty, and weak scientific
      rationales to guide treatment decisions. This trial will study subjects who have mild visual
      loss from IIH to (1) establish convincing, evidence-based treatment strategies for IIH to
      restore and protect vision, (2) follow subjects up to 4 years to observe the long-term
      treatment outcomes and (3) determine the cause of IIH. To meet those aims, the trial will be
      divided into a 12-month intervention phase and a 3-year observational phase. Subjects are not
      required to complete the observational phase of the study, but will be asked to do so and
      consented for the observational phase of the study at the conclusion of the intervention
      phase (12 months).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical Phase: Phase II Investigators: NORDIC Network sites Study Centers: 38 study centers
      Coordinating Center - University of Rochester Statistical Center - University of Rochester
      Study Period Planned enrollment duration: 2 years Planned duration of treatment: 6 months
      followed by open-label treatment Planned duration of follow-up: 4.5 years Study Objectives:
      The primary objective is determining the efficacy of diet plus acetazolamide vs diet alone in
      reducing or reversing visual loss in subjects with mild visual loss.

      The secondary objective is to identify proteomic and genetic risk factors for IIH by
      screening a large cohort of IIH patients and controls.

      Study Population This project will enroll 166 individuals with IIH who are 18-60 years of
      age. We anticipate that the population will be primarily composed of women in the
      childbearing years that are overweight. 154 control subjects will also be enrolled. Control
      subjects will be matched as closely as possibly by age, sex, race, ethnicity and weight to
      subjects enrolled at the site.

      Study Design: Multi-center, double-blind randomized intervention study followed by a 4-year
      observation period. Subjects will be randomized to diet and acetazolamide or diet and
      placebo. The study will use 250 mg acetazolamide or matching placebo tablets taken with food
      at meals and at bedtime. The subject will begin with one tablet four times daily, at meals
      and at bedtime for the first week. Beginning on Day 7, subjects will increase the dosage by 1
      tablet every 4 days until a final dosage of 4 tablets four times daily (4 grams) is reached
      or side effects prohibit increasing the dosage further. If the study drug is not tolerated at
      a dose of 250 mg, then 125 mg (1/2 tablet) will be tried. If this is not tolerated, no
      pharmacologic treatment will be given.

      After the 6 month visit, all subjects will transition from study medication to acetazolamide
      (open label) by replacing one tablet of study drug with 250 mg of acetazolamide every four
      days. The acetazolamide dose will be titrated in a manner similar to the initial study drug
      schedule to the maximum tolerated dose of acetazolamide. To avoid treating subjects (who may
      have initially been assigned to placebo) unnecessarily, any subject with grade 0-1
      papilledema will be tapered off study drug but not placed on acetazolamide unless they have
      persisting headaches or pulse-synchronous tinnitus. If so, they will be placed on
      acetazolamide regardless of the low papilledema grade. At the 9-month follow-up visit, we
      will make sure that the subjects' vision is stable after the transition off of study
      medication. After the 9 month visit, medication will be prescribed by the subject's treating
      physician. The intervention phase of the study will end at the subject's 12 month visit and
      subjects will be invited to participate in the observational phase of the study and consented
      to do so if willing.

      Number of Subjects: 166 subjects with IIH and 154 control subjects Main Inclusion Criteria

        1. Diagnosis of IIH by modified Dandy criteria

        2. Diagnosis of IIH for 6 weeks or less

        3. Age 18 to 60 years at time of diagnosis

        4. Reproducible visual loss present on automated perimetry (in eye with greatest loss)*

        5. perimetric mean deviation (PMD) -2 decibel (dB) up to -5 dB in the worst eye

        6. Presence of bilateral papilledema

        7. Able to provide informed consent or parental permission with appropriate assent

      Main Exclusion Criteria

        1. Total treatment of IIH of more than one week in the past six weeks

        2. Corticosteroids or surgery used for IIH treatment within the past two months

        3. Abnormalities on neurologic examination aside from papilledema and its related visual
           loss or VI nerve paresis (unless pre-existing and unrelated to IIH)

        4. Abnormal CT or MRI scan (intracranial mass, hydrocephalus, dural sinus thrombus or
           arteriovenous malformation) other than empty sella, dilated optic nerve sheath,
           flattened sclera, or secondary Chiari

        5. CSF pressure less than 200 mm water (patients may have repeat CSF pressure measurements
           if the first is normal or no opening pressure obtained)

        6. Abnormal CSF contents (increased cells, elevated protein, low glucose)

        7. Intraocular pressure currently &gt; 28 mm Hg or &gt; 30 mm Hg at any time in the past

        8. Refractive error &gt; +/- 6.00 sphere or &gt; +/- 3.00 cylinder in either eye

        9. Other disorders causing visual loss except for refractive error and amblyopia including
           cells in the vitreous or iritis

       10. Inability to provide reliable and reproducible visual field examination (failure to
           maintain fixation using an eye monitoring device, more than 15% false positive errors

       11. Abnormal blood work-up indicating a medical or systemic condition associated with raised
           intracranial pressure (ICP)

       12. Exposure to a drug, substance or disorder that has been associated with elevation of
           intracranial pressure within 2 months of diagnosis such as lithium, vitamin A,
           tetracycline, steroid withdrawal (see table in Manual of Procedures (MOP) for conditions
           and drugs)

       13. Other condition requiring diuretics, steroids or other pressure lowering agents
           including topiramate

       14. Presence of a medical condition such as renal stones that would contraindicate use of
           the study drugs (acetazolamide)

       15. Pregnancy or unwillingness for subject with childbearing potential to use contraception
           during the first year of the study

       16. Presence of a physical, mental, or social condition likely to affect follow-up (drug
           addiction, terminal illness, no telephone, homeless)

       17. Anticipation of a move from the site area within six months and unwillingness to return
           for follow-up.

      Route and Dosage Form: 250 mg acetazolamide tablets or matching placebo taken with food 4
      times daily. Subjects will titrate to a maximum dose of 4 tablets 4 times daily (4 grams) as
      tolerated. If a subject is not able to tolerate a dose of 250 mg, 125 mg (1/2 tablet) may be
      tried. If this is not tolerated, no pharmacologic treatment will be given.

      Duration of Treatment: 6 months of randomized treatment followed by open label acetazolamide
      treatment. After the 9-month visit medication will be prescribed by the subject's treating
      physician. The intervention phase of the study will end at Month 12 and the subject invited
      to continue in the observational phase.

      Primary Outcome Measure(s): The primary outcome measure is the change from baseline to Month
      6 in PMD (perimetric mean deviation) in the eye with the most severe initial visual loss.

      Secondary Outcome Measure: CSF pressure measurement by lumbar puncture Number of abnormal
      perimetry test locations Visual field examination ratings (improved, remained the same, or
      worsened) Papilledema grade QOL assessments Dietary Outcomes (BMI, Waist circumference,
      urinary sodium) Safety Outcomes: Adverse events will be tabulated by treatment group,
      severity, and perceived relationship to the study intervention Sample Size Considerations
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Perimetric Mean Deviation</measure>
    <time_frame>base line and 6 months</time_frame>
    <description>Treatment Effects on the Primary Outcome Variable, Mean change From Baseline to Month 6 in Perimetric Mean Deviation (PMD) in the Study Eye. Perimetric mean deviation is a measure of global visual field loss (mean deviation from age-corrected normal values), with a range of 2 to −32 dB; larger negative values indicate greater vision loss.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change of Papilledema Grade on Fundus Photography</measure>
    <time_frame>Baseline and 6 Months</time_frame>
    <description>Mean change at month 6 as compared to baseline. Frisén papilledema grade is an ordinal scale that uses ocular fundus features to rate the severity of papilledema; grade 0 indicates no features of papilledema and grade 5 indicates severe papilledema.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Function Questionnaire (VFQ-25)</measure>
    <time_frame>baseline</time_frame>
    <description>Visual Function Questionnaire (VFQ-25) total score, VFQ-25 10-item neuro-ophthalmic supplement total score: 0-100 (higher scores indicate better quality of life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity (No. of Correct Letters)</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">165</enrollment>
  <condition>Idiopathic Intracranial Hypertension</condition>
  <arm_group>
    <arm_group_label>Acetazolamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acetazolamide given in escalating doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Given in escalating &quot;dose&quot; (number of pill)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetazolamide</intervention_name>
    <description>Subjects will begin with four 250 mg tablets daily. Tablets will be divided among two doses, taken with meals. Beginning on day 7, subjects will increase the dose by 1 pill every week until 16 tablets daily is reached (4 grams acetazolamide or placebo) or side effects prohibit increasing the dosage further. Thus, subjects who are able to tolerate the study medication will reach the maximum dose by day 84.</description>
    <arm_group_label>Acetazolamide</arm_group_label>
    <other_name>naproxen</other_name>
    <other_name>acetaminophen</other_name>
    <other_name>aspirin</other_name>
    <other_name>ibuprofen</other_name>
    <other_name>codein</other_name>
    <other_name>butalbital</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will begin with four tablets daily. Tablets will be divided among two doses, taken with meals. Beginning on day 7, subjects will increase the dose by 1 pill every week until 16 tablets daily is reached (4 grams acetazolamide or placebo) or side effects prohibit increasing the dosage further. Thus, subjects who are able to tolerate the study medication will reach the maximum dose by day 84.</description>
    <arm_group_label>Sugar pill</arm_group_label>
    <other_name>naproxen</other_name>
    <other_name>acetaminophen</other_name>
    <other_name>aspirin</other_name>
    <other_name>ibuprofen</other_name>
    <other_name>codein</other_name>
    <other_name>butalbital</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Formal weight loss counselling program</intervention_name>
    <description>Teleconference, web-based from central location, using site visits and subject self-assessment tools</description>
    <arm_group_label>Acetazolamide</arm_group_label>
    <arm_group_label>Sugar pill</arm_group_label>
    <other_name>naproxen</other_name>
    <other_name>acetaminophen</other_name>
    <other_name>aspirin</other_name>
    <other_name>ibuprofen</other_name>
    <other_name>codein</other_name>
    <other_name>butalbital</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of IIH by modified Dandy criteria Signs and symptoms of increased
             intracranial pressure Absence of localizing findings on neurologic examination Absence
             of deformity, displacement, or obstruction of the ventricular system and otherwise
             normal neurodiagnostic studies, except for evidence of increased cerebrospinal fluid
             pressure (&gt;200 mm water). Abnormal neuroimaging except for empty sella turcica, optic
             nerve sheath enlargement, and smooth-walled non flow-related venous sinus stenosis or
             collapse106 should lead to another diagnosis Awake and alert No other cause of
             increased intracranial pressure present

          2. Diagnosis of IIH for 6 weeks or less

          3. Age 18 to 60 years at time of diagnosis

          4. Reproducible visual loss present on automated perimetry (in eye with greatest loss)

          5. Average PMD -2 dB up to -5 dB in the worst eye

          6. Presence of bilateral papilledema

          7. Able to provide informed consent

          8. Women of child-bearing potential must use an acceptable form of birth control during
             the intervention phase of the study. Acceptable forms include oral contraceptives,
             transdermal contraceptives,

        Exclusion Criteria:

          1. Total treatment of IIH of more than two weeks (except for acetazolamide which is
             limited to 1 week). For every day on treatment there must be a one-day washout period.

          2. Previous surgery for IIH including optic nerve sheath fenestration, CSF shunting
             procedures, subtemporal decompression and venous stenting

          3. Previous gastric bypass surgery

          4. Abnormalities on neurologic examination aside from papilledema and its related visual
             loss or VI nerve paresis

          5. Abnormal CT or MRI scan (intracranial mass, hydrocephalus, dural sinus thrombus or
             arteriovenous malformation) other than empty sella, unfolded optic nerve sheaths,
             flattened sclera, or smooth- walled venous stenosis

          6. CSF pressure less than 200 mm water (patients may have repeat CSF pressure
             measurements if the first is normal or no opening pressure obtained)

          7. Abnormal CSF contents: increased cells: &gt; 5 cells, elevated protein:

        &gt; 45 mg%, low glucose: &lt; 30 mg% (If the lumbar puncture produces a cell count compatible
        with a traumatic needle insertion, the patient does not need to be excluded if the CSF WBC
        after correction is 5 wbc/mm3 or less- see Operations Manual for calculation) 8.
        Intraocular pressure currently &gt; 28 mm Hg or &gt; 30 mm Hg at any time in the past 9.
        Refractive error &gt; +/- 6.00 sphere or &gt; +/- 3.00 cylinder in either eye with the following
        exceptions: Subjects with myopia of &gt;-6.00 D sphere but less than or equal to - 8.00 D
        sphere are eligible if 1)there are no abnormalities on ophthalmoscopy or fundus photos
        related to myopia that are associated with visual loss (such as staphyloma, retinal
        thinning in the posterior pole or more than mild optic disc tilt), and 2) the subject wears
        a contact lens for all perimetry examinations with the appropriate correction. If either
        the Site Investigator or the PRC director (or his designate) decides there are optic fundus
        abnormalities of myopia that are associated with visual loss, then 9. Subjects with
        hyperopia of &gt; +6.00 D but less than or equal to

          -  8.00 D sphere are eligible if 1) there is an unambiguous characteristic halo of
             peripapillary edema as opposed to features of a small crowded disc or other hyperopic
             change related to visual loss determined by the site investigator or the PRC director
             (or his designate) and 2) the subject wears a contact le 10. Other disorders causing
             visual loss except for refractive error and amblyopia including cells in the vitreous
             or iritis 11. Optic disc drusen on exam or in previous history 12. Presence of
             diagnosed untreated obstructive sleep apnea 13. Inability to provide reliable and
             reproducible visual field examination (failure to maintain fixation using an eye
             monitoring device, more than 15% false positive errors) 14. Abnormal blood work-up
             indicating a medical or systemic condition associated with raised ICP 15. Study blood
             results showing severe anemia, leukopenia or thrombocytopenia, renal failure, or
             hepatic disease, based on the Site Investigator's judgment 16. Type I diabetes or the
             presence of diabetic retinopathy 17. Exposure to a drug, substance or disorder that
             has been associated with elevation of intracranial pressure within 2 months of
             diagnosis such as lithium, vitamin A, various cyclines (see table in Operations Manual
             for conditions and drugs) 18. Other condition requiring diuretics, oral, I.V. or
             injectable steroids or other pressure lowering agents including topiramate (nasal,
             inhaled, or topical steroids are allowed since the systemic effects are small) 19.
             Presence of a medical condition such as renal stones that would contraindicate use of
             the study drug (acetazolamide) 20. Pregnancy or unwillingness for subject of
             childbearing potential to use contraception during the first year of the study 21.
             Breastfeeding mothers are excluded from participation unless willing to discontinue
             breastfeeding by the baseline visit 22. Presence of a physical, mental, or social
             condition likely to affect follow-up (drug addiction, terminal illness, no telephone,
             homeless) 23. Anticipation of a move from the site area within six months and
             unwillingness to return for follow-up at an IIHTT study site 24. Allergy to pupil
             dilating drops or narrow angles precluding safe dilation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Wall, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doheny Eye Center, University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Eye Care Group, PC</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bascom Palmer Eye Institute, University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuro-Ophthamology &amp; Balance Disorders Clinic</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Ophthamology and Visual Sciences, University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>55242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana State University Health Sciences Center - Earl K. Long Medical Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greater Baltimore Medical Center Department Of Ophthamology</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Universtiy - Wilmer Ophthamological Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bethesda Neurology, LLC</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts Eye and Ear Infirmary - Neuro-Ophthamology Service</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan State University Department of Neurology</name>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <zip>48823</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hosptial Research Institute</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University Eye Institute</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Jersey Medical School/University Physicians Associates of New Jersey</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Eye and Ear Infirmary</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester - Flaum Eye Institute</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook University</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University, Neurology Medical Service Group</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Eye Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raleigh Neurology Associates, PA</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forrest University Eye Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dean A. McGee Eye Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University - Casey Eye Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania, Department of Ophthamology</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Methodist Hospital: Methodist Eye Associates</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universtiy of Houston - University Eye Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Science Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah, John A. Moran Eye Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia - Department of Ophthalmology</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary: Rockyview General Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2V 1P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen's University - Hotel Dieu Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 5G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://NORDICclinicaltrials.com</url>
    <description>Organization Web-site</description>
  </link>
  <results_reference>
    <citation>NORDIC Idiopathic Intracranial Hypertension Study Group Writing Committee, Wall M, McDermott MP, Kieburtz KD, Corbett JJ, Feldon SE, Friedman DI, Katz DM, Keltner JL, Schron EB, Kupersmith MJ. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. JAMA. 2014 Apr 23-30;311(16):1641-51. doi: 10.1001/jama.2014.3312.</citation>
    <PMID>24756514</PMID>
  </results_reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>October 28, 2009</study_first_submitted>
  <study_first_submitted_qc>October 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2009</study_first_posted>
  <results_first_submitted>March 3, 2016</results_first_submitted>
  <results_first_submitted_qc>November 23, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 12, 2018</results_first_posted>
  <last_update_submitted>November 23, 2018</last_update_submitted>
  <last_update_submitted_qc>November 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>papilledema</keyword>
  <keyword>vision loss</keyword>
  <keyword>headache</keyword>
  <keyword>obesity</keyword>
  <keyword>women</keyword>
  <keyword>diplopia</keyword>
  <keyword>tinnitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Hypertension</mesh_term>
    <mesh_term>Pseudotumor Cerebri</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Acetazolamide</mesh_term>
    <mesh_term>Codeine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at 38 academic and private practice sites in North America from March 2010 to November 2012,with follow-up ending in June 2013.</recruitment_details>
      <pre_assignment_details>Randomization was stratified by site and included blocking to ensure balance among the treatment groups within a site after every 4 participants had been enrolled at that site.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Acetazolamide</title>
          <description>Acetazolamide given in escalating doses
Acetazolamide: Subjects will begin with four 250 mg tablets daily.</description>
        </group>
        <group group_id="P2">
          <title>Sugar Pill</title>
          <description>Given in escalating &quot;dose&quot; (number of pill)
Placebo: Subjects will begin with four tablets daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Acetazolamide</title>
          <description>Acetazolamide given in escalating doses
Acetazolamide: Subjects will begin with four 250 mg tablets daily.</description>
        </group>
        <group group_id="B2">
          <title>Sugar Pill</title>
          <description>Given in escalating &quot;dose&quot; (number of pill)
Placebo: Subjects will begin with four tablets daily.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="86"/>
            <count group_id="B2" value="79"/>
            <count group_id="B3" value="165"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.2" spread="6.9"/>
                    <measurement group_id="B2" value="30.0" spread="8.0"/>
                    <measurement group_id="B3" value="29.0" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="161"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="108"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108.1" spread="25.6"/>
                    <measurement group_id="B2" value="107.3" spread="24.5"/>
                    <measurement group_id="B3" value="107.7" spread="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <description>Body mass index is calculated as weight in kilograms divided by height in meters squared.</description>
          <units>Kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.0" spread="8.5"/>
                    <measurement group_id="B2" value="39.9" spread="8.1"/>
                    <measurement group_id="B3" value="39.9" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight change in the past 6 mo</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.7" spread="16.7"/>
                    <measurement group_id="B2" value="8.8" spread="16.9"/>
                    <measurement group_id="B3" value="9.8" spread="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Transient visual obscurations</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diplopia</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Constant visual loss</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Photophobia</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Headache</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pulsatile tinnitus</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Perimetric mean deviation</title>
          <description>Perimetric mean deviation is a measure of global visual field loss (mean deviation from age-corrected normal values), with a range of 2 to −32 dB; larger negative values indicate greater vision loss.</description>
          <units>dB</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Study eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-3.5" spread="1.2"/>
                    <measurement group_id="B2" value="-3.5" spread="1.1"/>
                    <measurement group_id="B3" value="-3.5" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fellow eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-2.3" spread="1.1"/>
                    <measurement group_id="B2" value="-2.3" spread="1.1"/>
                    <measurement group_id="B3" value="-2.3" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Papilledema grade (fundus photography) Study Eye</title>
          <description>Frisén papilledema grade is an ordinal scale that uses ocular fundus features to rate the severity of papilledema; grade 0 indicates no features of papilledema and grade 5 indicates severe papilledema.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Study eye 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study eye 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study eye 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study eye 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study eye 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Papilledema grade (fundus photography) Fellow eye</title>
          <description>Frisén papilledema grade is an ordinal scale that uses ocular fundus features to rate the severity of papilledema; grade 0 indicates no features of papilledema and grade 5 indicates severe papilledema.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Fellow eye 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fellow eye 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fellow eye 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fellow eye 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fellow eye 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIT-6 total score</title>
          <description>6-Item Headache Impact Test.
HIT-6 total score: 36-78 (higher scores indicate greater headache severity)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.3" spread="8.7"/>
                    <measurement group_id="B2" value="59.1" spread="9.3"/>
                    <measurement group_id="B3" value="59.7" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CSF pressure</title>
          <description>cerebrospinal fluid</description>
          <units>mm H2O</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="348.9" spread="94.1"/>
                    <measurement group_id="B2" value="342.0" spread="70.7"/>
                    <measurement group_id="B3" value="343.5" spread="86.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SF-36 component summary score</title>
          <description>Generic health-related quality of life was assessed with the 36-Item Short Form Health Survey - SF-36 consists of eight scaled scores (vitality, physical functioning bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health) : with weighted sums 0-100 (higher scores indicate better quality of life)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Physical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.4" spread="9.8"/>
                    <measurement group_id="B2" value="46.3" spread="8.2"/>
                    <measurement group_id="B3" value="45.8" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.2" spread="9.8"/>
                    <measurement group_id="B2" value="46.3" spread="8.2"/>
                    <measurement group_id="B3" value="45.8" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Perimetric Mean Deviation</title>
        <description>Treatment Effects on the Primary Outcome Variable, Mean change From Baseline to Month 6 in Perimetric Mean Deviation (PMD) in the Study Eye. Perimetric mean deviation is a measure of global visual field loss (mean deviation from age-corrected normal values), with a range of 2 to −32 dB; larger negative values indicate greater vision loss.</description>
        <time_frame>base line and 6 months</time_frame>
        <population>Sixty-nine of the 86 participants (80%) in the acetazolamide group completed follow-up compared with 57 of the 79 participants (72%) in the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>Acetazolamide</title>
            <description>Acetazolamide given in escalating doses
Acetazolamide: Subjects will begin with four 250 mg tablets daily.</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Given in escalating &quot;dose&quot; (number of pill)
Placebo: Subjects will begin with four tablets daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Perimetric Mean Deviation</title>
          <description>Treatment Effects on the Primary Outcome Variable, Mean change From Baseline to Month 6 in Perimetric Mean Deviation (PMD) in the Study Eye. Perimetric mean deviation is a measure of global visual field loss (mean deviation from age-corrected normal values), with a range of 2 to −32 dB; larger negative values indicate greater vision loss.</description>
          <population>Sixty-nine of the 86 participants (80%) in the acetazolamide group completed follow-up compared with 57 of the 79 participants (72%) in the placebo group.</population>
          <units>dB</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" spread="0.24"/>
                    <measurement group_id="O2" value="0.71" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>1.43</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change of Papilledema Grade on Fundus Photography</title>
        <description>Mean change at month 6 as compared to baseline. Frisén papilledema grade is an ordinal scale that uses ocular fundus features to rate the severity of papilledema; grade 0 indicates no features of papilledema and grade 5 indicates severe papilledema.</description>
        <time_frame>Baseline and 6 Months</time_frame>
        <population>Sixty-nine of the 86 participants (80%) in the acetazolamide group completed follow-up compared with 57 of the 79 participants (72%) in the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>Acetazolamide</title>
            <description>Acetazolamide given in escalating doses
Acetazolamide: Subjects will begin with four 250 mg tablets daily.</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Given in escalating &quot;dose&quot; (number of pill)
Placebo: Subjects will begin with four tablets daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change of Papilledema Grade on Fundus Photography</title>
          <description>Mean change at month 6 as compared to baseline. Frisén papilledema grade is an ordinal scale that uses ocular fundus features to rate the severity of papilledema; grade 0 indicates no features of papilledema and grade 5 indicates severe papilledema.</description>
          <population>Sixty-nine of the 86 participants (80%) in the acetazolamide group completed follow-up compared with 57 of the 79 participants (72%) in the placebo group.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.31" spread="0.11"/>
                    <measurement group_id="O2" value="-0.61" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fellow eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.14" spread="0.10"/>
                    <measurement group_id="O2" value="-0.52" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Function Questionnaire (VFQ-25)</title>
        <description>Visual Function Questionnaire (VFQ-25) total score, VFQ-25 10-item neuro-ophthalmic supplement total score: 0-100 (higher scores indicate better quality of life)</description>
        <time_frame>baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acetazolamide</title>
            <description>Acetazolamide given in escalating doses
Acetazolamide: Subjects will begin with four 250 mg tablets daily.</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Given in escalating &quot;dose&quot; (number of pill)
Placebo: Subjects will begin with four tablets daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Function Questionnaire (VFQ-25)</title>
          <description>Visual Function Questionnaire (VFQ-25) total score, VFQ-25 10-item neuro-ophthalmic supplement total score: 0-100 (higher scores indicate better quality of life)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.8" spread="14.1"/>
                    <measurement group_id="O2" value="82.1" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10-item neuro-ophthalmic supplement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.8" spread="15.4"/>
                    <measurement group_id="O2" value="75.0" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Acuity (No. of Correct Letters)</title>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acetazolamide</title>
            <description>Acetazolamide given in escalating doses
Acetazolamide: Subjects will begin with four 250 mg tablets daily.</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Given in escalating &quot;dose&quot; (number of pill)
Placebo: Subjects will begin with four tablets daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Acuity (No. of Correct Letters)</title>
          <units>correct letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.8" spread="5.1"/>
                    <measurement group_id="O2" value="55.6" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fellow Eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.3" spread="4.3"/>
                    <measurement group_id="O2" value="56.2" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Acetazolamide</title>
          <description>Acetazolamide given in escalating doses
Acetazolamide: Subjects will begin with four 250 mg tablets daily.</description>
        </group>
        <group group_id="E2">
          <title>Sugar Pill</title>
          <description>Given in escalating &quot;dose&quot; (number of pill)
Placebo: Subjects will begin with four tablets daily.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Rapidly failing vision</sub_title>
                <description>Rapidly failing vision requiring hospitalization and treatment with optic nerve sheath fenestration</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction of unknown origin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ventriculoperitoneal shunt malfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Transaminitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Elevated lipase with pancreatititis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Intracranial pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Live Birth</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Pulmnary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Caesarean section</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Ventriculo-peritoneal shunt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="86"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="86"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="86"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased CO2</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="86"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="86"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="86"/>
                <counts group_id="E2" events="16" subjects_affected="11" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="86"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="30" subjects_affected="26" subjects_at_risk="86"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="86"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated ALT</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="86"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="51" subjects_affected="41" subjects_at_risk="86"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="86"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="86"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Post-LP syndrome</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="86"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A limitation is the 19% withdrawal rate which may be due, in part, to the intensity of the visit schedule. Another limitation is the difficulty in the interpretation of the estimated treatment effect on PMD.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Michael Wall</name_or_title>
      <organization>University of Iowa Hospitals and Clinics</organization>
      <phone>319-353-3942</phone>
      <email>michael-wall@uiowa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

